KemPharm, the Coralville-based clinical stage specialty pharmaceutical company, this week announced enhancements to its intellectual property estate governing its portfolio of product candidates.

U.S. Patent No. 9,079,928 was issued to KemPharm. Extending through 2032, it provides composition of matter protection for KP 415, KemPharm's prodrug of methylphenidate, which is used to treat ADHD and narcolepsy. The U.S. Patent and Trademark Office (USPTO) has also issued an additional composition of matter patent for KP201, KemPharm's prodrug of hydrocodone (U.S. Patent No. 9,132,125).

KemPharm also announced it has received multiple ex-United States patents for KP511, its prodrug of hydromorphone, and KP303, its prodrug of Quietiapine, which is used to treat schizoprenia, biopolar disorder and depression.

The new U.S. and global patents add to the intellectual property covering KemPharm's prodrug pipeline, which also includes previously granted USPTO composition of matter patent protection for KP201, KP303 and KP511.

KemPharm CEO Travis Mickle, in a press release, said, "Securing and enhancing the intellectual property governing our proprietary prodrug portfolio, both in the United States and globally, is a critical component of KemPharm's business and development strategy, as it serves to protect our assets while demonstrating the highly differentiated aspects of our Ligand Activated Therapy prodrug technology."

Mr. Mickle added that the composition of matter patent for KP415 expands KemPharm's patent estate beyond the pain market, showcasing the broad applicability of its prodrug platform to create what it believes will be improved versions of approved and widely prescribed drugs.